Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 7 od 9  
Back povratak na rezultate
2006, vol. 63, br. 9, str. 813-818
Analiza gubitka heterozigotnosti tumor-supresor gena p53 i BRCA1 kod karcinoma ovarijuma
aKlinički centar Srbije, Klinika za ginekologiju i akušerstvo, Beograd
bUniverzitet u Beogradu, Medicinski fakultet, Institut za biologiju i humanu genetiku
cUniverzitet u Beogradu, Stomatološki fakultet

e-adresanovivana@eunet.yu
Ključne reči: jajnik; neoplazme; gubitak heterozigotnosti; gen p53; gen BRCA1
Sažetak
Uvod/cilj: Među genima uključenim u proces ovarijumske karcinogeneze pažnju privlače tumor-supresor geni p53 i BRCA1. Oba gena kontrolišu ćelijski ciklus, reparaciju DNK i apoptozu. Dok je p53 univerzalni "čuvar genoma" čija se inaktivacija nalazi u više od 50% maligniteta čoveka, mutacije BRCA1 se nalaze pre svega kod karcinoma dojke i ovrijuma. Istraživanje je sprovedeno sa ciljem da se utvrdi učestalost gubitka heterozigotnosti (LOH) u regionima gena p53 i BRCA1 kod karcinoma ovarijuma i da se ispita njegova korelacija sa stadijumom i prognozom bolesti. Metode. Ispitivanjem je obuhvaćeno 20 bolesnica sa potvrđenom dijagnozom karcinoma ovarijuma. Za molekularno genetičku analizu DNK izolovana je iz tumorskog tkiva i krvi kao kontrolnog zdravog tkiva iste osobe. Mikrosatelitni markeri u regionu gena p53 i BRCA1 umnožavani su PCR metodom, a analiza alelskog statusa i pojave LOH je vršena nakon poliakril-amidinom (PAA) gel elektroforeze. Rezultati. Oba analizirana mikrosatelitna markera bila su informativna u po 13 do 20 slučajeva (65%). U regionu gena p53 nađen je LOH u 4 od 13 slučajeva (30,7%). Po jedan od ovih tumora bio je histološkog gradusa G1 i G2, a dva histološkog gradusa G3, dok je FIGO stadijum u svim slučajevima bio IIIc. U regionu gena BRCA1 LOH je nađen u 5 od 13 slučajeva (38,5%). Od ovih uzoraka četiri su bila histološkog gradusa G2, a jedan histološkog gradusa G3. Po FIGO klasifikaciji jedan uzorak sa LOH bio je u stadijumu Ic, jedan u stadijumu IIIb, dok su tri bila u stadijumu IIIc. Istovremeni gubitak heterozigotnosti za oba ispitivana gena detektovan je u jednom uzorku histološkog gradusa G3, u stadijumu IIIc, što čini 7,7%. Zaključak. Učestalost LOH kod karcinoma ovarijuma iznosila je 30,7% u regionu gena p53, odnosno 38,5% u regionu gena BRCA1. Najveći broj tumora sa LOH bio je histološkog gradusa G2 ili G3, u kliničkom stadijumu IIIc, pa se može zaključiti da je ova pojava povezana sa kasnijom fazom razvoja bolesti.
Reference
Anderson, L.A., Friedman, L., Osborne-Lawrence, S., Lynch, E., Weissenbach, J., Bowcock, A., King, M.C. (1993) High-density genetic map of the BRCA1 region of chromosome 17q12-q21. Genomics, 17(3): 618-23
Arnold, J.M., Huggard, P.R., Cummings, M., Ramm, G.A., Chenevix-Trench, G. (2005) Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer, 92(11): 2024-31
Buller, R.E., Shahin, M.S., Holmes, R.W., Hatterman, M., Kirby, P.A., Sood, A.K. (2001) p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol, 184(5): 891-902; discussion 902-3
Chenevix-Trench, G., Kerr, J., Hurst, T., Shih, Y.C., Purdie, D., Bergman, L., Friedlander, M., Sanderson, B., Zournazi, A., Coombs, T., Leary, J.A., Crawford, E., Shelling, A.N., Cooke, I., Ganesan, T.S., Searle, J., Choi, C., Barrett, J.C., Khoo, S.K., Ward, B. (1997) Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: Clinicopathological correlations. Genes Chromosomes Cancer, 18(2): 75-83
Chopin, V., Leprince, D. (2006) Chromosome arm 17p13. 3: Could HIC1 be the one. Med Sci (Paris), 22(1): 54−61.(French)
Christie, M., Oehler, M.K. (2006) Molecular pathology of epithelial ovarian cancer. Journal of the British Menopause Society, 12(2): 57
Feltmate, C.M., Lee, K.R., Johnson, M., Schorge, J.O., Wong, K.K., Hao, K. (2005) Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas. Clinical Cancer Research, 11(21): 7651
Furlan, D., Carnevali, I., Marcomini, B., Cerutti, R., Dainese, E., Capella, C., i dr. (2006) The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clinical Cancer Research, 12(11): 3329
Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C.C. (1991) p53 mutations in human cancers. Science, 253(5015): 49-53
Holschneider, C.H., Berek, J.S. (2000) Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol, 19(1): 3-10
Jones, M.H., Nakamura, Y. (1992) Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer, 5(1): 89-90
Kato, H., Arakawa, A., Suzumori, K., Kataoka, N., Young, S. (2004) FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples. Exp Mol Pathol, 76(2): 138-42
Launonen, V., Mannermaa, A., Stenback, F., Kosma, V.M., Puistola, U., Huusko, P., Anttila, M., Bloigu, R., Saarikoski, S., Kauppila, A., Winqvist, R. (2000) Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: Correlation to clinicopathological variables. Cancer Genet Cytogenet, 122(1): 49-54
Leary, J.A., Doris, C.P., Boltz, E.M., Houghton, C.R., Kefford, R.F., Friedlander, M.L. (1993) Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. Int J Gynecol Cancer, 3, 5, 293-298
Lee-Jones, L. Ovary: Epithelial tumors. u: Atlas of Genetics and Cytogenetics in Oncology and Haematology, Available from: http://www.infobiogen.fr/services/
Miller, S.A., Dykes, D.D., Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16(3): 1215
Nussbaum, R.L., McInnes, R.R., Willard, H.F. (2001) Genes and cancer. u: Thomson M.W. [ur.] Thompson & Thompson's Genetics in medicine, Philadelphia: WB Saundres Company, 6th ed.p. 311-32
Otis, C.N., Krebs, P.A., Quezado, M.M., Albuquerque, A., Bryant, B., san Juan, X., Kleiner, D., Sobel, M.E., Merino, M.J. (2000) Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. Hum Pathol, 31(2): 233-8
Pecorino, L. (2005) Molecular biology of cancer: Mechanisms, targets, and therapeutics. Oxford ;New York: Oxford University Press
Pieretti, M., Hopenhayn-Rich, C., Khattar, N.H., Cao, Y., Huang, B., Tucker, T.C. (2002) Heterogeneity of ovarian cancer: Relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest, 20(1): 11-23
Popović, D.N. (1985) Ovarian carcinomas. u: Drobnjak P., Berić B., Đulović V. [ur.] Gynecology, Beograd: Medicinska knjiga, str. 112, Serbian
Quaresima, B., Faniello, MC., Baudi, F., Crugliano, T., Cuda, G., Costanzo, F. (2006) In vitro analysis of genomic instability triggered byBRCA1 missense mutations. Human Mutation, 27(7): 715
Quezado, M.M., Moskaluk, C.A., Bryant, B., Mills, S.E., Merino, M.J. (1999) Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol, 30(2): 203-7
Sambrook, J., Fritsch, E.F., Maniatis, T., ur. (1989) Molecular cloning: A laboratory manual. New York: Cold Spring Harbor Laboratory Press
Simpson, J.L., Elies, S. (2003) Genetics in obstetrics and gynecology. Philadelphia: W. B. Sounders
Tu, H., Gao, H.F., Fu, S.L., Chen, H. (2004) Quantitative analysis of circulating DNA in serum of cancer patients. Zhonghua Zhong Liu Za Zhi, 26(10): 606−8. (Chinese)
Wang, C., Horiuchi, A., Imai, T., Ohira, S., Itoh, K., Nikaido, T., Katsuyama, Y., Konishi, I. (2004) Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol, 202(2): 215-23
 

O članku

jezik rada: srpski
vrsta rada: originalan članak
DOI: 10.2298/VSP0609813P
objavljen u SCIndeksu: 02.06.2007.